SGLT2 inhibitors on SilverScript Choice (S5601-068)
Jardiance, Farxiga and the other SGLT2 inhibitors, for diabetes, heart failure and kidney disease, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Alaska
- Premium
- $94.90/month
- Deductible
- $615.00
3 of 6 SGLT2 inhibitors are covered on this plan. None require prior authorization.
3 aren't on the formulary, including Invokana and Steglatro.
- $36.69Tier 3
- $32.69Tier 3
- $1.22Tier 3
Not on the formulary
Invokana, Steglatro, Inpefa
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.